Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trabectedin + DOXIL versus DOXIL alone in platinum-sensitive recurrent ovarian, primary peritoneal, or fallopian tube cancer
MOH_2017-07-12_000355Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2013
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Ovarian Epithelial Adenocarcinoma, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Trabectedin + DOXIL with DOXIL alone (2 arms). Primary endpoint: Efficacy. Started Jul 2013; status: completed.
02
Drugs
trabectedinpegylated liposomal doxorubicin
03
Conditions
Ovarian Epithelial Adenocarcinomaprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2017-07-12_000355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-12_000355.